Strategic partnerships XtalPi is actively forming collaborations with pharma and biotech players (PharmaEngine, Pharmaceutera joint solution) and pursuing partnerships around GPCR targets and RNAi drug development, presenting ongoing opportunities for co-development, licensing, and platform-enabled research services.

AI and automation scale The company emphasizes a quantum physics based AI platform with wet lab robotics and cloud supercomputing to accelerate discovery, suggesting strong value propositions for CROs and biotechs seeking faster hit discovery, higher success rates, and scalable outsourcing arrangements.

Global footprint With operations in China and the U.S. and a blue-chip investor base, XtalPi appeals to multinational customers seeking regionally flexible collaborations, cross-border project execution, and access to diverse regulatory and clinical development ecosystems.

Robust financials & growth Strong revenue growth and profitability in 2025, plus substantial funding and a sizeable total funding amount indicate financial resilience and capacity to engage in larger, longer-term deals, strategic investments, and platform expansion.

Joint platform offerings Recent joint solutions with Pharmacelera and the Kodexia platform for siRNA drug development position XtalPi as a go-to partner for integrated AI-first discovery tools and first-principles approaches, enabling bundled services or co-marketing opportunities.